BAM
BIO icon

Belpointe Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Belpointe Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-164
Closed -$78.6K – 883
2023
Q1 		$78.6K Buy
164
+15
+10% +$7.02K ﹤0.01% 1452
2022
Q4 		$62.7K Buy
+149
New +$60.1K ﹤0.01% 1480

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Belpointe Asset Management's BIO Position: Q2 2023 in Review

Belpointe Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 164 shares — an estimated $78.6K sold.

Belpointe Asset Management first reported a position in BIO in Q4 2022 and held it in 2 quarters. The position peaked at $78.6K in Q1 2023. 468 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

  • Belpointe Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 164 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $78.6K.
  • Belpointe Asset Management first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Bio-Rad Laboratories Class A position peaked at $78.6K in Q1 2023.
  • 468 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.